MicroRNA aberrations including that of miR-24-2 have been reported in various
cancers. However, the target genes for miR-24-2 are yet to be identified and validated in invasive
breast cancer and the
triple-negative breast cancer (TNBC). Using in silico approaches and gene expression analyses, we identified and validated the target genes of miR-24-2 in invasive
breast cancer, majority of which were TNBC. We studied the translational potential of these target genes using
berberine in a TNBC cell line. Differentially expressed genes targeted by miR-24-2 were identified and analyzed for their survival effects using the The
Cancer Genome Atlas-Breast Invasive
Carcinoma (-BRCA) samples. Furthermore, we carried out
protein-
protein interaction, Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, gene expression, and Kaplan-Meier survival analyses using common targets of miR-24-2 in invasive
breast cancer/TNBC. We identified 11
biomarker candidate genes as crucial targets of miR-24-2. The survival of
breast cancer patients was significantly associated with the low expressions of nine genes, including RACGAP1, KIAA1199, TIMM17A, LYRM7, IL1R1, SLC1A3, DTX4,
L1CAM, and SAP30-like (SAP30L), and high expressions of two genes, SOD2 and HLA-DQB2. These in silico findings were validated by overexpressing miR-24-2 and assessing the expression pattern of these target genes in the TNBC MDA-MB-231 cells. miR-24-2 overexpression inhibited (by 20%; p < 0.001) cell proliferation and sensitized the anticancer effect of
berberine. In all, this study reports on the novel target genes of miR-24-2 in invasive
breast cancer/TNBC, and that miR-24-2 sensitizes MDA-MB-231 cells to
berberine. These data lend evidence for the translational potentials of miR-24-2 for invasive
breast cancer diagnostic and therapeutic innovation.